Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Biomatics Capital is a venture capital firm founded to support the transformation of healthcare and medicine through strategic investments. Established in Seattle, Washington, the firm focuses on the convergence of genomics and digital data to develop therapeutics, diagnostics, and delivery models aimed at improving patient outcomes and reducing costs in healthcare.
Currently, Biomatics Capital manages a portfolio that includes notable companies in the biotech and healthcare sectors. The firm has a strong emphasis on innovative technologies that can disrupt traditional healthcare markets. Their investment strategy is designed to identify and support outlier companies that demonstrate the potential for significant impact.
Biomatics Capital has been involved in key milestones, including leading substantial funding rounds and guiding companies through successful exits. The firm operates primarily in North America, with a focus on the United States.
Biomatics Capital invests in sectors such as digital health, medical technology, gene editing, and proteomics. The firm targets companies at various stages, including seed, Series A, and Series B funding rounds. Their investment strategy emphasizes identifying outlier companies with innovative ideas that have the potential to disrupt existing healthcare markets.
The firm is particularly interested in businesses that leverage the intersection of genomics and digital data to enhance patient outcomes. Biomatics Capital seeks to invest in therapeutics and diagnostics that can significantly improve healthcare delivery and reduce costs. Their approach includes a thorough evaluation of the potential for innovation and market disruption in the healthcare sector.
Biomatics Capital has a notable portfolio that includes:
Emily Leproust - Founder. Emily has a background in biotechnology and has been instrumental in guiding Biomatics Capital's investment strategy. Her expertise includes genomics and digital health, and she has a track record of successful investments in the healthcare sector.
To pitch Biomatics Capital, founders should email info@biomaticscapital.com with a detailed pitch deck. The deck should include information on the business model, market opportunity, and team. Response times may vary, but a well-structured pitch is likely to receive prompt attention.
In 2015, Biomatics Capital led a $120 million Series B funding round for Editas Medicine, which later achieved a $94.4 million IPO in 2016. This investment highlights the firm's commitment to supporting innovative companies in the biotech space.
What are Biomatics Capital's investment criteria?
Biomatics Capital focuses on innovative companies in the biotech and healthcare sectors, particularly those at the intersection of genomics and digital data. They target outlier companies with disruptive ideas that can enhance patient outcomes.
How can I pitch to Biomatics Capital?
Founders can reach out via email at info@biomaticscapital.com. A well-prepared pitch deck that outlines the business model, market opportunity, and team is essential.
What stages does Biomatics Capital invest in?
The firm invests at various stages, including seed, Series A, and Series B funding rounds, allowing them to support companies from early development through growth phases.
What makes Biomatics Capital different from other investors?
Biomatics Capital's unique focus on the convergence of genomics and digital data sets them apart. They prioritize investments in companies that have the potential to disrupt existing healthcare markets.
What is the geographic focus of Biomatics Capital?
Biomatics Capital primarily invests in North America, with a strong emphasis on the United States, allowing them to tap into a rich pool of innovative healthcare startups.
What kind of support do portfolio companies receive?
Biomatics Capital provides operational support, strategic guidance, and access to their network, helping portfolio companies navigate challenges and scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.